Treatment with zoledronate subsequent to denosumab in osteoporosis: a 2‐year randomized study
The study included 61 postmenopausal women and men above 50 years discontinuing denosumab after 4.6±1.6 years. After 12 months, lumbar spine BMD decreased by 4.0±0.8%, 4.1°C to 4.3°C in the 6M, 9M, and OBS groups. Treatment with ZOL did not fully prevent increased bone turnover and bone loss during the first year, however, CTX remained with the reference range and BMD was maintained during the second year.
